Funding agencies: This study was sponsored by UCB Pharma GmbH.
Article first published online: 23 SEP 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 13, pages 2431–2434, November 2011
How to Cite
Hellriegel, H., Raethjen, J., Deuschl, G. and Volkmann, J. (2011), Levetiracetam in primary orthostatic tremor: A double-blind placebo-controlled crossover study. Mov. Disord., 26: 2431–2434. doi: 10.1002/mds.23881
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 22 NOV 2011
- Article first published online: 23 SEP 2011
- Manuscript Accepted: 15 JUN 2011
- Manuscript Revised: 10 JUN 2011
- Manuscript Received: 7 FEB 2011
- clinical neurology;
- clinical trials;
- orthostatic tremor;
In a double-blind crossover study we evaluated the antitremor effect of a 4-week treatment with either escalating dosages of levetiracetam or placebo in orthostatic tremor.
Twelve patients with orthostatic tremor participated in the study. Primary end point was improvement in stance duration. Secondary end points were total track length of the sway path and tremor total power. The patients' impression of impairment was assessed by a visual analog scale and quality of life by the SF-36.
We found no significant effect of dosage or treatment on stance duration (P = .175), total track length (P = .690), total power (P = .280), or visual analog scale (P =.735). Neither was SF-36 differentially changed by levetiracetam or placebo (SF-36, Physical Component Summary: P = .079; SF-36, Mental Component Summary: P = .073). Side effects like dizziness, fatigue, or nausea were only mild to moderate.
Levetiracetam is ineffective in the treatment of orthostatic tremor. © 2011 Movement Disorder Society